ARYA Sciences Acquisition Corp. III (NASDAQ:ARYA) announced in an 8-K filing that its shareholders approved its combination with Nautilus Biotechnology at a special meeting earlier today.
The SPAC did not disclose redemption figures, but noted that 75.68% of shares participated in the vote, and the combination was approved nearly unanimously.
The transaction is now expected to close on June 9 with with the combined entity’s shares commencing trading on the Nasdaq under the symbols “NAUT” respectively on June 10.
The parties initially announced their $905 million deal on February 8. Nautilus is working to create a machine-learning technology platform for testing and mapping proteins and serve as an accelerant in biopharmaceutical research.
Although all measures on ARYA’s ballot passed by wide margins, some advisory governing document proposals received pushback. For a full list of proposals and vote tallies, click HERE.
ADVISORS
- Morgan Stanley is acting as lead financial advisor to Nautilus Biotechnology, with Cowen also acting as financial advisor to Nautilus Biotechnology.
- Wilson Sonsini Goodrich & Rosati, P.C., is acting as legal counsel to Nautilus Biotechnology.
- Jefferies LLC and Goldman Sachs & Co. LLC are acting as financial advisors to Arya III as well as private placement agents.
- Kirkland & Ellis LLP is acting as legal counsel to Arya III.
AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...
At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...
Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...
At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...
Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...